PE20151595A1 - Compuestos de pirazol-amida y sus usos farmaceuticos - Google Patents

Compuestos de pirazol-amida y sus usos farmaceuticos

Info

Publication number
PE20151595A1
PE20151595A1 PE2015001993A PE2015001993A PE20151595A1 PE 20151595 A1 PE20151595 A1 PE 20151595A1 PE 2015001993 A PE2015001993 A PE 2015001993A PE 2015001993 A PE2015001993 A PE 2015001993A PE 20151595 A1 PE20151595 A1 PE 20151595A1
Authority
PE
Peru
Prior art keywords
pirazol
amide compounds
pharmaceutical uses
diabetes
hyperlactacidemia
Prior art date
Application number
PE2015001993A
Other languages
English (en)
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20151595A1 publication Critical patent/PE20151595A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78Benzoic acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion esta referida a compuestos derivados de pirazol-amida de Formula l, o sus sales farmaceuticamente aceptables, los cuales tienen actividad inhibidora de la piruvato deshidrogenasa cinasa (PDHK) y son empleados como agentes profilacticos o terapeuticos en el tratamiento de la diabetes, sindrome de resistencia a la insulina, sindrome metabolico. hiperglucemia, hiperlactacidemia, complicaciones diabeticas, insuficiencia cardiaca, cardiomiopatia, isquemia miocardica, infarto de miocardio, entre otras. Tambien se incluyen composiciones farmaceuticas que los contienen
PE2015001993A 2013-03-15 2014-03-14 Compuestos de pirazol-amida y sus usos farmaceuticos PE20151595A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18

Publications (1)

Publication Number Publication Date
PE20151595A1 true PE20151595A1 (es) 2015-11-24

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001993A PE20151595A1 (es) 2013-03-15 2014-03-14 Compuestos de pirazol-amida y sus usos farmaceuticos

Country Status (31)

Country Link
US (4) US9040717B2 (es)
EP (3) EP3805205A1 (es)
JP (6) JP6208603B2 (es)
KR (1) KR102226096B1 (es)
CN (1) CN105051015B (es)
AU (1) AU2014230569B2 (es)
BR (1) BR112015022077A2 (es)
CA (1) CA2904985C (es)
CL (1) CL2015002608A1 (es)
CY (1) CY1120173T1 (es)
DK (1) DK2975028T3 (es)
ES (1) ES2663789T3 (es)
HK (1) HK1215808A1 (es)
HR (1) HRP20180635T1 (es)
HU (1) HUE036672T2 (es)
IL (1) IL241355B (es)
LT (1) LT2975028T (es)
ME (1) ME03090B (es)
MX (1) MX2015012743A (es)
MY (1) MY182884A (es)
NO (1) NO2975028T3 (es)
PE (1) PE20151595A1 (es)
PH (1) PH12015501993B1 (es)
PL (1) PL2975028T3 (es)
PT (1) PT2975028T (es)
RS (1) RS57188B1 (es)
RU (1) RU2664532C2 (es)
SG (1) SG11201507327TA (es)
SI (1) SI2975028T1 (es)
TW (1) TWI633885B (es)
WO (1) WO2014142290A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
SG11201507327TA (en) * 2013-03-15 2015-10-29 Japan Tobacco Inc Pyrazole-amide compound and medicinal uses therefor
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
BR112019001447A2 (pt) * 2016-07-29 2019-05-07 Japan Tobacco, Inc. método de produção para composto pirazol-amida
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MX2020008126A (es) * 2018-02-01 2020-09-18 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos.
JPWO2020054734A1 (ja) 2018-09-11 2021-08-30 日本たばこ産業株式会社 ピラゾール−アミド化合物を含有する慢性腎臓病の治療又は予防剤
US20220409548A1 (en) 2019-03-04 2022-12-29 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
KR20220149688A (ko) * 2020-03-04 2022-11-08 니뽄 다바코 산교 가부시키가이샤 축합 3환성 화합물 및 그의 의약 용도
AU2022337617A1 (en) * 2021-09-01 2024-04-18 Japan Tobacco Inc. Nitrogen-containing tricyclic compound and pharmaceutical use thereof
KR20240045387A (ko) * 2022-09-28 2024-04-08 (주)제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
SI1620118T1 (sl) 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
RU2006107371A (ru) 2004-02-20 2006-09-10 Астеллас Фарма Инк. (Jp) Флуореновые производные
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
RU2011147232A (ru) * 2009-04-22 2013-05-27 Астеллас Фарма Инк. Производное карбоновой кислоты
TW201506015A (zh) * 2013-03-15 2015-02-16 Japan Tobacco Inc 茀化合物的水合物以及其結晶
SG11201507327TA (en) * 2013-03-15 2015-10-29 Japan Tobacco Inc Pyrazole-amide compound and medicinal uses therefor
JP2015028010A (ja) 2013-07-01 2015-02-12 日本たばこ産業株式会社 フルオレン−アミド化合物およびその医薬用途
TW201536749A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 吡唑-醇化合物及其醫藥用途

Also Published As

Publication number Publication date
AU2014230569A1 (en) 2015-10-08
CL2015002608A1 (es) 2016-03-04
CY1120173T1 (el) 2018-12-12
CA2904985C (en) 2021-07-20
EP3805205A1 (en) 2021-04-14
HK1215808A1 (zh) 2016-09-15
JP2020189855A (ja) 2020-11-26
JP2019194197A (ja) 2019-11-07
EP2975028A1 (en) 2016-01-20
SG11201507327TA (en) 2015-10-29
ES2663789T3 (es) 2018-04-17
NO2975028T3 (es) 2018-07-21
HRP20180635T1 (hr) 2018-06-01
SI2975028T1 (en) 2018-07-31
RS57188B1 (sr) 2018-07-31
PH12015501993A1 (en) 2016-01-11
CN105051015A (zh) 2015-11-11
RU2015144182A3 (es) 2018-03-06
CN105051015B (zh) 2018-09-25
KR102226096B1 (ko) 2021-03-09
JP2018021061A (ja) 2018-02-08
HUE036672T2 (hu) 2018-07-30
PT2975028T (pt) 2018-03-29
US20200163937A1 (en) 2020-05-28
US9040717B2 (en) 2015-05-26
JP2022000453A (ja) 2022-01-04
TW201501711A (zh) 2015-01-16
KR20150131221A (ko) 2015-11-24
EP2975028A4 (en) 2016-08-17
JP6208603B2 (ja) 2017-10-04
RU2664532C2 (ru) 2018-08-20
IL241355B (en) 2019-03-31
PL2975028T3 (pl) 2018-10-31
US20140296315A1 (en) 2014-10-02
JP2015024984A (ja) 2015-02-05
DK2975028T3 (en) 2018-03-12
MX2015012743A (es) 2016-02-19
RU2015144182A (ru) 2017-04-24
LT2975028T (lt) 2018-04-10
TWI633885B (zh) 2018-09-01
EP2975028B1 (en) 2018-02-21
EP3348545A1 (en) 2018-07-18
IL241355A0 (en) 2015-11-30
US20180256547A1 (en) 2018-09-13
ME03090B (me) 2019-01-20
MY182884A (en) 2021-02-05
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
JP2018188449A (ja) 2018-11-29
WO2014142290A1 (ja) 2014-09-18
US20160074364A1 (en) 2016-03-17
AU2014230569B2 (en) 2017-11-23
PH12015501993B1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
PE20151595A1 (es) Compuestos de pirazol-amida y sus usos farmaceuticos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
ECSP15014941A (es) Compuestos antivíricos para el vsr
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
GT201300215A (es) Inhibidores de glucosilceramida sintasa
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
UY31616A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica
CU20130036A7 (es) Triazina-oxidazoles
CO6670520A2 (es) Lactmas sustituidas con piperidinio como moduladores de gpr119
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2015000170A (es) Compuestos químicos
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa

Legal Events

Date Code Title Description
FG Grant, registration